Background: Non-Hodgkin lymphoma (NHL) and Hodgkin lymphoma (HL) are increased in populations with immune dysfunction, including people living with HIV; however, there is little evidence for to what degree immunological and virological factors differently affect NHL and HL risk. Methods: Data from the Data Collection on Adverse events of Anti-HIV Drugs Study cohort were analyzed to identify independent risk factors for NHL and HL using hazard ratios (HRs), focusing on current and cumulative area under the curve (AUC) measures of immunological and virological status. Variables with different associations with NHL and HL were identified using marginal Cox models. All statistical tests were two-sided. Results: Among 41 420 people followed for 337 020 person-years, 392 developed NHL (incidence rate ¼ 1.17/1000 person-years of follow-up [PYFU], 95% confidence interval [CI] ¼ 1.06 to 1.30) and 149 developed HL (incidence rate ¼ 0.44/1000 PYFU, 95% CI ¼ 0.38 to 0.52). Higher risk of both NHL and HL was associated with lower current CD4 cell count (adjusted HR [aHR] of NHL for CD4 <100 vs > 599 cells/mm 3 ¼ 8.08, 95% CI ¼ 5.63 to 11.61; HL ¼ 4.58, 95% CI ¼ 2.22 to 9.45), whereas higher current HIV
Use of combination antiretroviral treatment (cART) in people living with HIV (PLWH) has led to a decline in the incidence of non-Hodgkin lymphoma (NHL; with the exception of Burkitt lymphoma [BL]) but not Hodgkin lymphoma (HL) (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) . Recent estimates indicate that the incidence rates of NHL and HL remain elevated in PLWH compared with the general population, with NHL incidence estimated to be around 10-fold higher (11) (12) (13) and HL incidence estimated to be around 11-fold higher (9, 12) .
In PLWH, the pathogenesis of NHL and HL is thought to be driven by a combination of latent infection with Epstein-Barr virus (EBV) and HIV-associated immune suppression and dysfunction (14) (15) (16) . The interaction between HIV infection, immune suppression and dysfunction, and EBV co-infection is thought to differ between NHL and HL, as well as between NHL subtypes (17) . For example, approximately half of BL cases occur at relatively preserved CD4 cell counts and are not EBV related (18) . Primary brain lymphomas (PBCNSL) often occur at very low CD4 levels; however, a lack EBV-specific CD4 T-cell function has been shown in PLWH people prior to PBCNSL development, irrespective of absolute CD4 cell counts (19) . Almost all HL cases are EBV related in PLWH, and although HL is associated with low CD4 cell counts (8, 18, 20, 21) , it is not as strong as for PBCNSL or diffuse large B-cell lymphomas.
Several prior studies have suggested that the risk factors and strengths of associations differ for NHL and HL in the context of PLWH (22) (23) (24) (25) (26) (27) (28) (29) . For example, older age has been linked to NHL; however, several studies have reported no association between HL incidence and age in PLWH (20, (30) (31) (32) (33) (34) . Many studies have identified an association between lower current CD4 cell count and both NHL and HL incidence (5, 20, 31, (35) (36) (37) (38) (39) . However, both current and cumulative HIV-VL have been linked with NHL incidence, independent of CD4 (34, 40) , an association not usually reported for HL (37) . The START study demonstrated that immediate cART statistically significantly reduced the risk of infection-related cancers, independent of CD4 and HIV-VL, suggesting that HIV-associated cancer risk is mediated through other mechanisms such as immune activation and reduced immune surveillance, above and beyond the depletion of CD4 cell counts (41) .
Although there are many studies investigating incidence of NHL and HL since the introduction of cART and associated risk factors, to our knowledge no studies have directly compared the risk factors. Therefore, we aimed to identify independent risk factors of NHL and HL and to identify factors that differentially affect NHL and HL risk in order to develop an understanding of different mechanistic pathways, which may then suggest different preventive approaches for reducing NHL and HL risk.
Methods

The Data Collection on Adverse Events of Anti-HIV Drugs Study
The Data Collection on Adverse events of Anti-HIV Drugs Study (D:A:D) is a prospective cohort collaboration established in 1999; the data set includes more than 49 000 HIV-1-positive people in Europe, the United States, and Australia. The D:A:D Study has been described in detail previously (42) . Data for routine clinical care, including demographic factors, HIV treatment, laboratory values, and AIDS-defining events (including NHL [43] ) are collected at enrollment and annually thereafter. Non-AIDSdefining cancers, such as HL, have been routinely collected and validated since January 1, 2004 . Detailed information on all non-AIDS-defining cancers is collected via designated case report forms, including date of diagnosis, type/location of cancer, stage, and histology/cytology report or other applied diagnostic methods, such as imaging and biochemical assays, and this information is supplemented by submitted source documentation supporting the way of diagnosis. NHL is further characterized by histological type (BL, diffuse large B-cell lymphoma [DLBCL] , PBCNSL, and other or unknown). All events are centrally validated at the D:A:D coordinating center by a medical doctor, with a proportion of complicated cases selected to be reviewed by an external oncologist. Events are regularly monitored for accuracy, with random monitoring at participating sites to ensure complete case ascertainment. All participating cohorts followed local national guidelines or regulations regarding patient consent and ethical review, and written consent from individual participants was obtained when this was required according to the local and/or national study requirements. In particular, of the countries represented by the participating cohorts, only Switzerland and Australia require specific ethical approval for D:A:D in addition to that required for their national cohorts (Swiss HIV Cohort Study and the Australian HIV Observational Database), both of which have obtained this approval.
Hodgkin and Non-Hodgkin Lymphomas
We investigated the association between immunological and virological factors and two main outcomes: 1) first diagnosis of NHL and 2) first diagnosis of HL during follow-up. Baseline was defined as the latest of date of study entry, first reported CD4 cell count, or January 1, 2004, and people were followed from baseline until the earliest of NHL or HL diagnosis, last visit plus six months, death, or February 1, 2015.
Statistical Analysis
We investigated the associations between nadir and current CD4 cell count, and current and area under the curve (AUC) of HIV-VL and each outcome. The AUC of HIV-VL refers to the area under each individual's viral load curve (44) , which was calculated using all HIV-VL measures since entry into D:A:D. Formally, it can be interpreted as the total number of copies/mL of HIV-RNA accumulated over time. For example, an AUC of HIV-VL of 10 000 copies/Ml per year is equal to having a HIV-VL of 10 000 copies/mL for one year or an HIV-VL of 1000 copies/mL for 10 years. Due to the high correlation between nadir and current CD4, only one measure was included in the analysis according to the lowest Akaike information criterion (AIC) for both NHL and HL. Current and AUC of HIV-VL were not strongly correlated, and therefore both were included in the same model.
Incidence rates of NHL and HL were calculated by calendar year of follow-up. Separate Cox regression models were used to identify factors associated with NHL and HL, focusing on current and nadir CD4, and current and AUC of HIV-VL. Models were adjusted for baseline factors (sex, HIV transmission mode, ethnicity, calendar year of baseline) and current factors ( (45) was used to identify factors that differently affected NHL and HL risk. The models were used to jointly calculate and compare adjusted hazard ratios (aHRs) for NHL and HL for all current and historical measures of HIV-VL and CD4 cell count (separately), adjusting for variables listed previously. In order to fit a more parsimonious model, variables not associated with either NHL or HL incidences were assumed to have a similar association for both NHL and HL. The remaining variables were allowed to vary according to outcome. The marginal Cox models differed to those used to identify independent risk factors with minor differences in adjustments (fixed and outcome-specific variables) that give slightly different estimates. The ratio of the adjusted HRs (RHR) was used to identify factors with different risk profiles for NHL and HL, which we have termed "differential factors." Variables for which the 95% confidence interval for the RHR cross 1 indicate a similar association between the risk factor and both HL and NHL.
All statistical tests were two-sided. A P value of less than .05 was considered statistically significant. All statistical analyses were performed using SAS 9.4 (Statistical Analysis Software, Cary, NC). All bivariate associations were tested using chisquare tests for categorical variables and Kruskal-Wallis tests for numerical variables.
Results
Study Population
There were 41 420 people included in the analysis contributing 337 020 PYFU with a median follow-up of 9. 
Baseline Characteristics
Baseline characteristics of the study population, as well as those who developed NHL or HL during follow-up, are shown in Table 1 . Overall, 17.4% were age 50 years or older at baseline, 72.9% were male, and 43.8% acquired their HIV through sex between men; 49.9% were of white ethnicity, and 40.9% had unknown ethnicity. Just over half were on cART (51.8%) at baseline, with a median cART duration of 1. , and the median HIV-VL was 260 copies/mL (IQR 50-20 400 copies/mL).
Crude Incidence Rates Over Time
The crude incidence rates of NHL and HL by calendar year are shown in Figure 1 . The crude incidence of NHL declined by 13.3% per year (95% CI ¼ 10.3 to 16.2%), from an incidence rate of 1.96 (95% CI ¼ 1.48 to 2.58) events/1000 PYFU in 2004 to 0.32 (95% CI ¼ 0.17 to 0.62) in 2014/15. In 2014/15, the incidence of NHL was similar to HL (HL incidence ¼ 0.36, 95% CI ¼ 0.19 to 0.66); however, HL incidence was stable over time (change per year ¼ -2.7%, 95% CI ¼ -7.7% to 2.6%).
Independent Risk Factors for NHL and HL
Current and nadir CD4 cell counts were considered for inclusion in the main analysis. Both associated with NHL in adjusted analyses, whereas only current CD4 was associated with HL. However, current CD4 was the strongest immune marker for both NHL and HL, so it was the only immunological marker included in multivariable models (provided the best statistical fit, measured as by the AIC).
Independent risk factors of NHL and HL from a multivariable model are shown in Table 2 . For example, a higher rate of NHL was strongly associated with lower current CD4 cell count category (CD4 <100 vs >599 cells/mm 3 
Differences in Risk Factors for NHL and HL
Factors that were associated with either NHL or HL in Table 2 were jointly modeled to identify factors that were differently associated with NHL and HL (differential factors). Current HIV-VL was a differential factor, as demonstrated by the increase in ratio of the aHRs with higher HIV-VL category ( Figure 2 ). For example, the RHRs were 2.52 (95% CI ¼ 1.32 to 4.81) and 4.57 (95% CI ¼ 2.20 to 9.50) in those with current HIV-VL 50-1000 copies/mL and more than 1000 copies/mL, relative to less than 50 copies/mL, respectively, indicating a progressively stronger association with NHL than for HL with higher current HIV-VL. A similar result was found for the AUC of HIV-VL, which was also a differential factor. Current CD4 was not a differential factor as the 95% confidence interval of the ratio of the aHRs for each CD4 cell count category relative to CD4 200-299 cells/mm 3 contained 1, indicating no evidence that lower CD4 cell count was differently associated with NHL and HL. Age was a differential risk factor as the ratio of the aHRs of people older than age 60 years relative to those age 30 to 39 years was 3.06 (95% CI ¼ 1.43 to 6.55), indicating a relatively higher increase in rates of NHL than HL for people in this older age group. Finally, smoking status was a differential factor, as the ratio of the aHRs for current smokers relative to never smokers was 0.49 (95% CI ¼ 0.28 to 0.83), indicating a statistically significantly higher relative increase in risk for HL in this group. No other factors investigated were differential factors.
NHL Subtypes
Of the 392 NHL, 42 were BL (10.7%), 25 were PBCNSL (6.4%), 65 were DLBCL (16.6%), and 260 were unknown (66.3%) ( Table 3) . People with known and unknown NHL subtype had similar characteristics at diagnosis. Slightly more people with known subtype reported being on protease inhibitors (known subtype 
Discussion
This study is the first to attempt to identify differences in the underlying pathology of NHL and HL in PLWH by directly comparing the immunological and virological risk factors for each and identifying differences. Higher current and cumulative exposure to HIV-VL were stronger risk factors for NHL than HL. Although current CD4 was a strong predictor of both, there was no evidence of a different association between with NHL and HL. In this study, the crude incidence of NHL declined steadily over time while HL incidence remained stable. The trends over time are not surprising and have been reported before (1-10); however, our study is one of the first to show that incidence of NHL and HL is similar in PLWH in recent years. This highlights a shift away from the cancers with a strong link with immune deficiency and the need for a better understanding of how generalized immune dysfunction (beyond low CD4 cell counts) can facilitate lymphoma development.
The risk of NHL and HL differed according to current and accumulated HIV-VL, but not current CD4 cell count. Our results indicate a similar pathological requirement of immunodeficiency for both NHL and HL development; however, an important distinction is the involvement of HIV-VL in NHL but not HL development. This indicates that HIV infection may contribute to lymphomagenesis of NHL through additional immune dysfunction not captured by supressed CD4 (46), possibly though reduced immune surveillance for proteins expressed by cells infected with latent EBV, immune activation, and/or CD8 dysfunction, leading to depleted response from EBV-specific CD8 cytotoxic cells (14) (15) (16) 19, 47, 48) . Some studies have found that levels of circulating free light chains have predictive value of NHL in PLWH, which supports the involvement of immune activation (49, 50) . In addition, the ratio and percentage of CD8 cells have been shown to be predictive of HL (30) and may also be predictive of EBV-associated NHL (19, 51) . Alternatively, HIV may play a more direct role in lymphomagenesis (46, 52) , with HIV-derived p17 secreted within lymphoid tissues possibly promoting lymphoma development by inducing changes to the microenvironment (52) . Furthermore, the CD4-independent effect of HIV-VL was statistically significant and consistent across the known subtypes studied. This was surprising in the case of BL, which has little association with CD4 (53).
Smoking status had a different association with HL and NHL, where risk of HL was elevated in current smokers. Research in the general population has indicated that smoking may play an etiological role in HL, particularly EBV positive (54, 55) . Almost all HL in PLWH is EBV related; therefore, smoking presents as one of the few modifiable risk factors for this cancer, which emphasizes the importance of smoking cessation strategies in PLWH. Age had a different association with NHL and HL, where people older than age 50 years had a higher relative increase in the rate of NHL than for HL, which is consistent with previous studies (14, 20, 30, 32, 33, 56) . This may reflect increases in immune activation and inflammation associated with aging and further supports the hypothesis that immune dysfunction beyond low CD4 is involved in the pathology (57) . The lack of association between either HCV or HBV status and NHL or HL is in contrast to results from the COHERE study, which found a statistically significant association between both HCV and HBV and NHL risk in treated patients (58) , and two meta analyses (59, 60) , although other studies have failed to show a convincing association (20, 61, 62) . This study has many advantages. The D:A:D study contains follow up on more than 40 000 people and allows for the analysis of a relatively large number of prospectively collected and validated NHL and HL events. Furthermore, the D:A:D data contain highly detailed demographic, HIV, and health-related factors collected over a long follow-up period. However, the limitations need to be considered. There are several known risk factors for NHL and HL that are not collected in D:A:D, for example, autoimmune disorders and family history. Furthermore, NHL subtype is only reported by a subset of cohorts in D:A:D, and as a result it was missing on 66% of people; however, the characteristics of those with and without subtype information were similar. D:A:D does not collect additional markers of immune suppression or dysfunction, or EBV viral load. And finally, this is an observational study, and it is possible that confounding due to unmeasured or unknown factors remains and the causality of the associations presented here cannot be determined. It should also be kept in mind that NHL is treated as a single entity the main analysis; however, there is considerable heterogeneity in etiology between NHL subtypes (63) . Several studies from the COHERE collaboration have been referred to; however, these studies are in naïve patients, of which the proportion in D:A:D is very low, resulting in minimal overlap between the two studies.
In conclusion, whereas CD4 depletion similarly increased risk of both types of lymphomas, current and accumulated HIV-VL was more predictive of NHL than HL. This suggests that NHL development is related to both CD4 cell depletion and added immune dysfunction derived from ongoing HIV replication. This latter factor was not associated with HL risk. These findings stress the importance of early HIV diagnosis and treatment, and of ensuring sustained viral suppression. †P value of the Wald chi-square statistic with respect to a chi-square distribution with one degree of freedom. All statistical tests of significance were two-sided. ‡Models were additionally adjusted for log10 current HIV-VL and log10 of area under the curve of HIV-VL, in addition to age, sex, mode of HIV acquisition, race, current smoking status, cumulative time on cART. §Models were additionally adjusted for log2 current CD4, in addition to age, sex, mode of HIV acquisition, race, current smoking status, cumulative time on cART.
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